| Document |
Document Title |
|
WO/2012/062870A1 |
This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate useful in the treatment of patients infected with the hepatitis C virus (HCV).
|
|
WO/2012/062869A1 |
This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate of formula (I) which inhibits the hepatitis C virus (HCV).
|
|
WO/2012/060482A1 |
The present invention relates to a CDK-inhibiting pyrrolopyrimidinone carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing same as an active ingredient for preventing or treati...
|
|
WO/2012/056976A1 |
Provided is a novel compound capable of inhibiting cardiac adenylate cyclase. The compound is a compound represented by formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof. (In the formula, R1, R2 and R3 independe...
|
|
WO/2011/115513A9 |
This invention provides a cytosine analogue, a method of preparation of a cytosine analogue, a DNA rhethyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated w...
|
|
WO/2012/053917A1 |
The object of the invention are nucleotide analogues, antiviral pro-nucleotides, a use of nucleotide analogues and pharmaceutical composition, a phosphorylating agent for synthesis of nucleotide analogue, and a method of synthesis of nuc...
|
|
WO/2012/050264A1 |
Provided is novel selenyl-methyluracil compounds, and more particularly, a pharmaceutical composition for enhancing the effect of radiation treatment, which comprises at least one compound selected from the group consisting of the seleny...
|
|
WO/2012/049464A1 |
The invention relates to reagents for use in investigating the presence and activation state of G-proteins. There is provided a compound for use in the identification of the activity of G- proteins. The compound comprises a G-protein bin...
|
|
WO/2012/048063A2 |
Cyanine compounds having the general formula I, conjugates, complexes, and compositions comprising the cyanine compounds are provided. Fluorescence resonance energy transfer (FRET) dye pairs and viability dyes are also provided.
|
|
WO/2012/048202A2 |
The invention is directed to processes for synthesizing bicyclic nucleoside antiviral compounds and for synthesizing the intermediates used in the process. The invention is also directed to novel intermediate compounds useful in the proc...
|
|
WO/2012/045999A1 |
Phosphorodiamidate derivatives of e.g. gemcitabine are provided for use in treating cancer. In one embodiment, the two amidate motifs each comprises NR'R" where R' is H and R" is CR5R6CO2R7, where R6 is H, R5 is the side chain, including...
|
|
WO/2012/048013A2 |
This invention is directed to novel compounds of formula (I) having the structure that are useful in the treatment of viral infections in mammals mediated, at least in part, by a virus in the Flaviviridae family of viruses. Methods of tr...
|
|
WO/2012/040124A1 |
Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are meth...
|
|
WO/2012/039448A1 |
An asymmetric auxiliary group which is useful for the efficient production of a nucleic acid derivative modified with a phosphorus atom and having high stereoregularity; and a compound represented by general formula (I) or general formul...
|
|
WO/2012/038097A1 |
The present invention relates to the use of a compound of the formula (A), its use in medicine and for the prophylaxis and/or treatment of infectious diseases. Also disclosed are pharmaceutical formulations containing at least one of the...
|
|
WO/2012/040126A1 |
Disclosed herein are phosphoroamidate nucleotide analogs, methods of synthesizing phosphoroamidate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the...
|
|
WO/2012/040127A1 |
Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the...
|
|
WO/2012/035436A1 |
Compounds of Formula (I) and (I') are disclosed, as are methods for making such compounds. Compositions and methods for treating various disease conditions including cancer and non-cancer diseases associated with vascular proliferation a...
|
|
WO/2012/032513A1 |
The present invention provides pharmaceutical compositions and methods for treatment and management of osteoarthritis using certain dinucleotide boranophosphate derivatives or nucleoside boranophosphate derivatives. The invention further...
|
|
WO/2012/031539A1 |
The present invention relates to the field of pharmachemistry. Disclosed are fluorinated and azide-substituted pyrimidine nucleoside derivatives, and preparation methods and uses thereof. The structural formula is as shown (I). These com...
|
|
WO/2012/024776A1 |
The invention relates to the chemical synthesis of oligoribonucleotides. In another aspect, the invention relates to compounds of formula (II) : processes for making these compounds, and the use thereof in the chemical synthesis of oligo...
|
|
WO/2012/024625A2 |
Disclosed are compounds of nucleoside 5 '-triphosphates of formula (I), or derivatives thereof, or pharmaceutically acceptable salts of said nucleoside 5 '-triphosphates or said derivatives, wherein the Base of formula (I) is Adenine (A)...
|
|
WO/2012/023572A1 |
The purpose of the present invention is to provide a 5-formyl nucleic acid production process whereby a 5-formyl group can be introduced into a nucleoside located at any position. This 5-formyl nucleic acid production process involves a ...
|
|
WO/2012/019284A1 |
The present invention relates to a pharmaceutical composition for treating a neoplasm, a preneoplasm, a proliferative disorder and/or a precancerous lesion, the use of such compositions for the treatment of the listed conditions, and met...
|
|
WO/2011/134444A9 |
The invention relates to substitution derivatives of N6-benzyladenosine-5'- monophosphate of the general formula (I), wherein (R)n represents 1 to 4 substituents (n is in the range 1 - 4), which can be the same or different, and R is sel...
|
|
WO/2011/109113A9 |
|
|
WO/2012/017400A1 |
The present invention relates to a novel synthesis method for acyl-pantetheine derivatives. The present invention further relates to the use of said synthesized acyl-pantetheine derivatives as a starting material in the enzymatic synthes...
|
|
WO/2012/018697A1 |
The present invention provides methods that more accurately predict melting temperatures for duplex oligomers. The invented methods predict the Tm of chimeric duplexes containing various amounts of locked nucleic acid modifications in ol...
|
|
WO/2012/017434A2 |
The present invention generally relates to Rel proteins as a novel therapeutic target for treating bacterial threats. More specifically, the present invention relates to a novel class of compounds of formula (I) which inhibit RelA and/or...
|
|
WO/2012/012902A1 |
Provided herein are compositions and methods to enhance the absorption of S- adenosylmethionine (SAMe) and methods of treating various disorders or diseases using non- parenteral SAMe formulations with enhanced-absorption and improved bi...
|
|
WO/2012/012465A1 |
Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas (la) and (lb): The compounds of Formula la and lb are useful for the treatment Hepatitis C infections.
|
|
WO/2012/012776A1 |
Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (I): wherein the 1 ' position of the nucleoside sugar is substituted. The compounds, comp...
|
|
WO/2012/011114A2 |
The present invention provides specific double-stranded DNA/RNA binding compounds having a polymeric structure, which are in fact, triplex forming molecules capable of binding tightly and specifically to predetermined sequences in the ma...
|
|
WO/2012/008228A1 |
Disclosed is a method for oxidizing alcohols, wherein it is possible to efficiently oxidize primary alcohols and secondary alcohols and to achieve high reaction efficiency even when air is used as the bulk oxidant. Specifically disclosed...
|
|
WO/2012/009666A2 |
The present invention relates to methods of synthesizing 18F-FMAU. In particular, 18F-FMAU is synthesized using one-pot reaction conditions in the presence of Friedel-Crafts catalysts. The one-pot reaction conditions are incorporated int...
|
|
WO/2011/111501A9 |
Disclosed is RNA that includes a translated region having a 5' cap structure as well as a 5' side start codon and 3' side stop codon on the ends. A nucleoside compound in which a group represented by formula (I) is bonded to position 8 o...
|
|
WO/2011/160216A2 |
As described herein there is provided novel precursors/synthons, and their chemical and radiochemical derivatives and methods of use thereof.
|
|
WO/2011/158904A1 |
Disclosed is an effective and safe therapeutic agent for inflammatory diseases such as sepsis, pneumonia, and inflammatory bowel diseases, which contains adenosine N1-oxide or a derivative thereof as an active ingredient.
|
|
WO/2011/159471A2 |
The disclosure provides linked purine pterin compounds and analogues thereof that are novel HPPK inhibitors. The HPPK inhibitors described herein are compounds and the pharmaceutically acceptable salts thereof of general Formula I: (I). ...
|
|
WO/2011/156278A1 |
The present invention provides novel 3', 5 '-linked bicyclic nucleosides and oligomeric compounds prepared therefrom. The bicyclic nucleosides provided herein are useful for enhancing one or more properties of the oligomeric compounds th...
|
|
WO/2011/153874A1 |
Provided is a crystallization process of cyclic adenosine 3',5'-monophosphate, which comprises the following steps: 1) reacting an aqueous solution of cyclic adenosine 3',5'-monophosphate with a base to obtain a salt of cyclic adenosine ...
|
|
WO/2011/156202A1 |
Provided herein are 2'-amino and 2'-thio bicyclic nucleosides and oligomenc compounds prepared therefrom. The novel bicyclic nucleosides provided herein are expected to be useful for enhancing one or more properties of the oligomeric com...
|
|
WO/2011/152155A1 |
Disclosed is a method for producing a (2R)-2-fluoro-2-C-methyl-D-ribono-γ-lactone precursor of an open-ring fluorinated compound [In the formula, Me represents a methyl group, R1 represents an alkyl group or an alkyl substituent, P1 and...
|
|
WO/2011/151493A1 |
The invention relates to glycosylated derivatives of formula I, wherein the designations for the each substituent are indicated in the description. Said compounds can be used as α-glycosidase inhibitors.
|
|
WO/2011/143593A1 |
The invention provides conjugate compounds, pharmaceutical compositions, therapeutic methods, and kits for use in treating cell proliferation disorders, such as cancer. The conjugates comprise a redox-modulating compound, such as a lipoi...
|
|
WO/2011/133871A2 |
The present invention provides compounds of formula (1). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with th...
|
|
WO/2011/132801A1 |
Disclosed is a nucleic acid base analog with quenching characteristics and fluorescence and application thereof. Specifically disclosed is a quencher characterized by having a 2-nitropyrrole structure shown by formula (I). [In formula (I...
|
|
WO/2011/130289A1 |
The present disclosure relates to the field of nucleic acid chemistry, specifically to 5-position modified uridines as well as phosphoramidite and triphosphate derivatives thereof. The present disclosure also relates to methods of making...
|
|
WO/2011/123672A1 |
Disclosed herein is a compound represented by formula 1 or its hydrate thereof in crystalline or crystal-like form.
|
|
WO/2011/123668A2 |
Disclosed herein are phosphorus-containing actives, their use as actives for treating diseases, and a stereoselective process for preparing the same. Also disclosed herein are useful synthetic intermediates and processes for preparing th...
|
